Dyadic International, Inc. (OTC Pink: DYAI) is a global biotechnology company located in Jupiter, Florida with its main research and development operations located in The Netherlands.
Dyadic is focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, biochemical, industrial enzyme and biopharmaceutical industries.
Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins.
Dyadic’s technologies overcome the inadequacy of existing gene discovery and product development techniques which have limited capabilities to efficiently access the full spectrum of earth’s biodiversity. Dyadic’s unique technology increases the likelihood that each time a useful gene is discovered, it can also be expressed and then mass-produced.
Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce.
Serving diverse industries
Dyadic currently sells more than 55 liquid and dry enzyme products to more than 150 industrial customers in approximately 50 countries for a broad range of industries including biofuels, bio-based chemicals, biopharmaceuticals, animal health and nutrition, pulp & paper, textiles, food and beverage, and nutraceuticals.